Literature DB >> 4042416

Successful tumour immunotherapy: possible role of antibodies to anti-inflammatory factors produced by neoplasms.

M Nelson, D S Nelson, P B Spradbrow, V K Kuchroo, P A Jennings, G J Cianciolo, R Snyderman.   

Abstract

Phenol-saline tumour extracts, active in the immunotherapy of bovine ocular squamous cell carcinoma (BOSCC), were used to immunize mice. The immunized mice became resistant to the depression of delayed type hypersensitivity (DTH) reactions by products of BOSCC cells or cultured mouse or rat tumour cells. They also showed partial resistance to the growth of an unrelated tumour. Monoclonal antibodies to a type C retrovirus protein, p15E, also induced resistance to the depression of DTH by products of BOSCC and mouse tumours. It is suggested that successful immunotherapy of BOSCC is associated with the induction of resistance to anti-inflammatory or immunosuppressive tumour cell products, allowing the operation of host defences, and that these products share antigenic determinants with a retrovirus protein.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4042416      PMCID: PMC1577247     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Abrogation of lymphocyte blastogenesis by a feline leukaemia virus protein.

Authors:  L E Mathes; R G Olsen; L C Hebebrand; E A Hoover; J P Schaller
Journal:  Nature       Date:  1978-08-17       Impact factor: 49.962

2.  Immunosuppressive properties of a virion polypeptide, a 15,000-dalton protein, from feline leukemia virus.

Authors:  L E Mathes; R G Olsen; L C Hebebrand; E A Hoover; J P Schaller; P W Adams; W S Nichols
Journal:  Cancer Res       Date:  1979-03       Impact factor: 12.701

3.  An inhibitor of macrophage chemotaxis produced by neoplasms.

Authors:  R Snyderman; M C Pike
Journal:  Science       Date:  1976-04-23       Impact factor: 47.728

4.  Influence of dose and route of antigen injection on the immunological induction of T cells.

Authors:  P H Lagrange; G B Mackaness; T E Miller
Journal:  J Exp Med       Date:  1974-03-01       Impact factor: 14.307

5.  Delayed hypersensitivity in mice induced by intravenous sensitization with sheep erythrocytes: evidence for tuberculin type delayed hypersensitivity of the reaction.

Authors:  A Mitsuoka; T Teramatsu; M Baba; S Morikawa; K Yasuhira
Journal:  Immunology       Date:  1978-03       Impact factor: 7.397

6.  Regression of bovine ocular carcinoma by treatment with a mycobacterial vaccine.

Authors:  S J Kleinschuster; H J Rapp; D C Lueker; R A Kainer
Journal:  J Natl Cancer Inst       Date:  1977-06       Impact factor: 13.506

7.  Macrophages and resistance to tumours. I. Inhibition of delayed-type hypersensitivity reactions by tumour cells and by soluble prducts affecting macrophages.

Authors:  M Nelson; D S Nelson
Journal:  Immunology       Date:  1978-02       Impact factor: 7.397

8.  Depression of macrophage function by a factor produced by neoplasms: a merchanism for abrogation of immune surveillance.

Authors:  M C Pike; R Snyderman
Journal:  J Immunol       Date:  1976-10       Impact factor: 5.422

9.  An evaluation of leukocyte adherence inhibition in the immunodiagnosis of colorectal cancer.

Authors:  W J Halliday; A E Maluish; P M Stephenson; N C Davis
Journal:  Cancer Res       Date:  1977-07       Impact factor: 12.701

10.  Antiinflammatory effects of murine malignant cells.

Authors:  R M Fauve; B Hevin; H Jacob; J A Gaillard; F Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

View more
  8 in total

1.  Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: immunosuppression, immunogenicity, and relation to immunosuppressive tumor products.

Authors:  M Nelson; D S Nelson; G J Cianciolo; R Snyderman
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Inhibition of rat yolk sac tumour growth in vivo by a monoclonal antibody to the retroviral molecule P15E.

Authors:  M Lindvall; H O Sjögren
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Depression of cell-mediated immunity by tumour cell products: induction of resistance by immunotherapeutically active extracts of bovine ocular squamous cell carcinoma.

Authors:  M Nelson; D S Nelson; V K Kuchroo; P B Spradbrow; P A Jennings
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

4.  Immunotherapy with monoclonal antibodies directed against the immunosuppressive domain of p15E inhibits tumour growth.

Authors:  M S Lang; E Hovenkamp; H F Savelkoul; P Knegt; W Van Ewijk
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

5.  Inhibition of interleukin-2 production by tumor cell products and by CKS-17, a synthetic retroviral envelope peptide.

Authors:  M Nelson; D Nelson
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Suppression of the generation of lymphokine-activated killer (LAK) cells by serum-free supernatants of in vitro maintained tumour cell lines.

Authors:  P J Guillou; C W Ramsden; S S Somers; P C Sedman
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

7.  Increased titers of neutralizing antibodies after immunization with both envelope proteins of the porcine endogenous retroviruses (PERVs).

Authors:  Joachim Denner; Debora Mihica; Danny Kaulitz; Christa-Maria Schmidt
Journal:  Virol J       Date:  2012-11-05       Impact factor: 4.099

8.  Expression of a suppressive p15E-related epitope in colorectal and gastric cancer.

Authors:  S Foulds; C H Wakefield; M Giles; J Gillespie; J F Dye; P J Guillou
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.